Study analysis · Lancet · 2009
One daily shot beats two daily shots for diabetes — and it’s not what you think.
Taking one diabetes shot a day works better and causes fewer side effects than taking two shots a day.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
We don't know enough about how the study was done to say if one medicine really works better than another. The title says it was a fair test, but the summary doesn't prove it, so we can't trust any claims about which drug is better.
What’s the bottom line?
Two different diabetes medicines were tested: one shot once a day (liraglutide) and another shot twice a day (exenatide).
How strong is this study?
This study's quality is a mystery because we only saw the short summary. It's like hearing that a science fair project won first place, but not seeing how they did the experiment—we can't tell if it was done right or just lucky.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Randomization, blinding, and control group status are not explicitly confirmed in the abstract; therefore, causation cannot be established.
No Conflicts
No conflicts of interest identified
No conflicts identified
The provided text is a brief conclusion snippet with no disclosure of funding, author affiliations, or conflicts of interest. No basis exists to infer bias or industry influence.
Key takeaways
- 01
The once-a-day shot lowered blood sugar more and caused fewer side effects than the twice-a-day shot.
- 02
For people with type 2 diabetes, this means fewer shots and better blood sugar control with less risk of low blood sugar.
Practical takeaways
If you're managing type 2 diabetes and struggling with multiple daily injections, ask your doctor if liraglutide once daily could be an option.
This conclusion is based only on the abstract; full methodology, patient demographics, and side effect rates are unknown.
low confidenceWhy this study matters
Once-Daily vs. Twice-Daily Shots
Liraglutide, taken once daily, led to significantly greater improvements in blood sugar control compared to exenatide, which requires two daily injections. It was also generally better tolerated.
For people with type 2 diabetes, fewer injections mean less hassle, less pain, and potentially better adherence — all while getting better results.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Two different diabetes medicines were tested: one shot once a day (liraglutide) and another shot twice a day (exenatide).
Research results
The once-a-day shot lowered blood sugar more and caused fewer side effects than the twice-a-day shot.
What this means - more context
For people with type 2 diabetes, this means fewer shots and better blood sugar control with less risk of low blood sugar.
Compare liraglutide once daily with exenatide twice daily for type 2 diabetes in terms of glycaemic control and tolerability.
Liraglutide once daily provided significantly greater improvements in glycaemic control than exenatide twice daily and was generally better tolerated, suggesting it may be a preferable option when weight loss and hypoglycaemia risk are concerns.
Methods Used
Randomised, parallel-group, multinational, open-label trial (LEAD-6) over 26 weeks; methodology details not available in abstract.
Main Finding
Liraglutide once daily led to significantly greater improvements in glycaemic control than exenatide twice daily and was generally better tolerated.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No effect sizes or p-values reported in abstract
- •Open-label design may introduce bias, not confirmed in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you're managing type 2 diabetes and struggling with multiple daily injections, ask your doctor if liraglutide once daily could be an option.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Lower probability
on the GRADE evidence scale
We don't know enough about how the study was done to say if one medicine really works better than another. The title says it was a fair test, but the summary doesn't prove it, so we can't trust any claims about which drug is better.
No conflicts of interest were detected in this study. No score impact.
Weaknesses
- Full methodology not available - based on abstract only
- Randomization status unknown
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Two different diabetes medicines were tested: one shot once a day (liraglutide) and another shot twice a day (exenatide).
Research results
The once-a-day shot lowered blood sugar more and caused fewer side effects than the twice-a-day shot.
What this means - more context
For people with type 2 diabetes, this means fewer shots and better blood sugar control with less risk of low blood sugar.
Compare liraglutide once daily with exenatide twice daily for type 2 diabetes in terms of glycaemic control and tolerability.
Liraglutide once daily provided significantly greater improvements in glycaemic control than exenatide twice daily and was generally better tolerated, suggesting it may be a preferable option when weight loss and hypoglycaemia risk are concerns.
Methods Used
Randomised, parallel-group, multinational, open-label trial (LEAD-6) over 26 weeks; methodology details not available in abstract.
Main Finding
Liraglutide once daily led to significantly greater improvements in glycaemic control than exenatide twice daily and was generally better tolerated.
Confidence Level
Limited - based on abstract only, full methodology not available
Study Flags
Red Flags
- •Full text not available - methodology details cannot be verified
- •No effect sizes or p-values reported in abstract
- •Open-label design may introduce bias, not confirmed in abstract
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Practical Takeaways
If you're managing type 2 diabetes and struggling with multiple daily injections, ask your doctor if liraglutide once daily could be an option.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Human RCT
Subject
Lower probability
on the GRADE evidence scale
We don't know enough about how the study was done to say if one medicine really works better than another. The title says it was a fair test, but the summary doesn't prove it, so we can't trust any claims about which drug is better.
No conflicts of interest were detected in this study. No score impact.
Weaknesses
- Full methodology not available - based on abstract only
- Randomization status unknown
- Blinding status unknown
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study's quality is a mystery because we only saw the short summary. It's like hearing that a science fair project won first place, but not seeing how they did the experiment—we can't tell if it was done right or just lucky.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
0 / 100
- Randomizationrandomization unclear
- Blindingblinding unclear
- Control groupno control group
- Sample sizeno sample size reported
- Follow-upno follow-up reported
100 / 100
0 / 100
- P-valuesno p-values reported
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 520 / 100
Probability of being correct
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
This design cannot establish causation — the findings describe an association, not a cause. Randomization, blinding, and control group status are not explicitly confirmed in the abstract; therefore, causation cannot be established.
No Conflicts
No conflicts of interest identified
No conflicts identified
The provided text is a brief conclusion snippet with no disclosure of funding, author affiliations, or conflicts of interest. No basis exists to infer bias or industry influence.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
8 researchersIf this is your work, this is how we attribute it on Fit Body Science. John B. Buse is listed as the lead author.
- University of North Carolina at Chapel Hill
Cited in 1 claim